Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$56.64

0.22 (0.39%)

06:21
08/22/17
08/22
06:21
08/22/17
06:21

Bristol-Myers treatment of stage IIb to IV melanoma gets FDA orphan designation

Reference Link

  • 08

    Sep

  • 11

    Sep

  • 24

    Sep

  • 09

    Nov

  • 05

    Mar

BMY Bristol-Myers
$56.64

0.22 (0.39%)

08/16/17
LEER
08/16/17
NO CHANGE
Target $34
LEER
Outperform
Leerink sees competitor setback in RCC opportunity for Exelixis
Leerink analyst Michael Schmidt notes that Bristol-Myers (BMY) reported top-line results from the Phase III CheckMate-214 trial investigating Opdivo in combination with Yervoy versus Sutent in intermediate and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma, or RCC. While directionally positive, the trial missed the co-primary endpoint of improving progression-free survival with statistical significance, he notes, adding that this raises the regulatory bar for Bristol-Myers' IO combination at least until positive overall survival data are available likely in mid-2019, which he thinks will be positively received by Exelixis (EXEL) investors. Following the news, Schmidt believes Exelixis continues to look well positioned in RCC, He reiterates an Outperform rating and $34 price target on the latter's shares.
08/16/17
FBCO
08/16/17
NO CHANGE
Target $58
FBCO
Neutral
Reaction to Bristol-Myers CM-214 data 'overly pessimistic,' says Credit Suisse
Credit Suisse analyst Vamil Divan notes that Bristol-Myers (BMY) reported topline data for the Phase 3 CheckMate-214 study of Opdivo + Yervoy in 1st line renal cell carcinoma. For the first two co-primary endpoints in the trial, the results were mixed, with the combination showing an improved objective response rate as compared to Pfizer's (PFE) Sutent but narrowly missing statistical significance on improved progression-free survival, he adds. With the revenue opportunity being pushed out and potentially down due to added competition, the analyst feels modest weakness in Bristol-Myers shares is reasonable, although the actual decline seen seems "a little excessive." Divan reiterates a Neutral rating and $58 price target on Bristol-Myers shares.
08/16/17
PIPR
08/16/17
NO CHANGE
Target $29
PIPR
Overweight
After Bristol data, Piper continues to expect approval for Exelixis
Bristol-Myers Squibb (BMY) reported "mixed" top-line Phase III CheckMate-214 data on 1,070 front-line metastatic renal cell carcinoma patients, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. He continues to expect a front-line renal cell carcinoma supplemental new drug application for Exelixis' (EXEL) Cabometyx in Q3 with approval next year. Tenthoff anticipates Cabometyx use in front-line RCC expanding the current market opportunity before ultimately showing IO combination benefit. The analyst reiterates an Overweight rating on Exelixis shares with a $29 price target.
08/08/17
GSCO
08/08/17
NO CHANGE
GSCO
Bristol-Myers stock could be worth $64-$74 per share, says Goldman Sachs
Goldman Sachs analyst Jami Rubin believes that Bristol-Myers could be worth $64-$74 per share ,depending on the outcome of a trial of its CM-227 cancer treatment. The analyst notes that if the trial is successful, the company will have the only IO treatment that works in conjunction with the CTLA-4 protein receptor, and Rubin says this will be "particularly meaningful"if patients taking CM-227 show.a higher overall survival rate than those taking chom combos. Rubin thinks the stock could be worth $59-$75 per share in a takeover with no value for CM-227, and the analyst says that at $50 per share the stock is reflecting no value for the company's first line NSCLC treatment. Rubin keeps the stock on the Americas Buy List.

TODAY'S FREE FLY STORIES

SYBX

Synlogic

$18.73

-0.52 (-2.70%)

09:40
09/19/17
09/19
09:40
09/19/17
09:40
Initiation
Synlogic initiated  »

Synlogic initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

, KORS

Michael Kors

09:40
09/19/17
09/19
09:40
09/19/17
09:40
Options
Unusually active option classes on open September 19th »

Unusual total active…

KSU

Kansas City Southern

KORS

Michael Kors

AAOI

Applied Optoelectronics

$66.29

7.99 (13.71%)

RAD

Rite Aid

NKE

Nike

M

Macy's

EFX

Equifax

INTC

Intel

VIX

Volatility Index S&P 500 Options

AMD

AMD

$13.08

0.56 (4.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 23

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 28

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

  • 16

    Nov

NKE

Nike

09:37
09/19/17
09/19
09:37
09/19/17
09:37
Recommendations
Nike analyst commentary  »

Nike risk/reward remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

SMBK

SmartFinancial

$23.88

0.38 (1.62%)

09:36
09/19/17
09/19
09:36
09/19/17
09:36
Hot Stocks
SmartFinancial, Capstone Bancshares holders approve merger-related proposals »

SmartFinancial and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:35
09/19/17
09/19
09:35
09/19/17
09:35
General news
FX Action: USD-CAD »

FX Action: USD-CAD edged…

PG

Procter & Gamble

09:34
09/19/17
09/19
09:34
09/19/17
09:34
Hot Stocks
Peltz says Procter & Gamble should have bought Method Soap »

Nelson Peltz of Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CORI

Corium

$10.16

0.25 (2.52%)

, NEOS

Neos Therapeutics

$8.70

-0.5 (-5.43%)

09:33
09/19/17
09/19
09:33
09/19/17
09:33
Conference/Events
Mizuho to hold a conference »

Biotechnology CNS Deep…

CORI

Corium

$10.16

0.25 (2.52%)

NEOS

Neos Therapeutics

$8.70

-0.5 (-5.43%)

VYGR

Voyager Therapeutics

$17.36

1.01 (6.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

NVAX

Novavax

$1.12

-0.02 (-1.75%)

09:32
09/19/17
09/19
09:32
09/19/17
09:32
Hot Stocks
Novavax initiates Phase 1/2 trial of NanoFlu vaccine in older adults »

Novavax announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BSMX

Santander Mexico

09:32
09/19/17
09/19
09:32
09/19/17
09:32
Downgrade
Santander Mexico rating change  »

Santander Mexico…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPLR

Xplore Technologies

$3.50

-0.2 (-5.41%)

09:31
09/19/17
09/19
09:31
09/19/17
09:31
Hot Stocks
Xplore Technologies secures Android rugged tablet order »

Xplore Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 30

    Nov

SNE

Sony

09:31
09/19/17
09/19
09:31
09/19/17
09:31
Downgrade
Sony rating change  »

Sony downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
09/19/17
09/19
09:30
09/19/17
09:30
General news
The U.S. August housing starts report »

The U.S. August housing…

BSX

Boston Scientific

09:29
09/19/17
09/19
09:29
09/19/17
09:29
Hot Stocks
Boston Scientific's HeartLogic Diagnostic shows positive risk detection ability »

Boston Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:28
09/19/17
09/19
09:28
09/19/17
09:28
Hot Stocks
Ubiquiti CEO to host Investor Update on September 26 »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

HQY

HealthEquity

$45.77

0.65 (1.44%)

09:26
09/19/17
09/19
09:26
09/19/17
09:26
Conference/Events
HealthEquity participates in a conference call with Chardan »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:26
09/19/17
09/19
09:26
09/19/17
09:26
Hot Stocks
Ubiquiti Board approves additional $100M stock repurchase program »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:23
09/19/17
09/19
09:23
09/19/17
09:23
Earnings
Ubiquiti narrows Q1 revenue view to $240M-$250M, consensus $234.5M »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

LNDC

Landec

$12.80

-0.2 (-1.54%)

09:22
09/19/17
09/19
09:22
09/19/17
09:22
Hot Stocks
Landec provides update on impact from extreme weather events »

Landec provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BOBE

Bob Evans

$72.93

1.02 (1.42%)

, POST

Post Holdings

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Bob Evans (BOBE),…

BOBE

Bob Evans

$72.93

1.02 (1.42%)

POST

Post Holdings

AZO

AutoZone

TLGT

Teligent

$6.90

-0.29 (-4.03%)

WBA

Walgreens Boots Alliance

$82.60

0.1 (0.12%)

RAD

Rite Aid

APOG

Apogee Enterprises

$44.98

0.18 (0.40%)

EFX

Equifax

ALDX

Aldeyra

$9.10

0.2 (2.25%)

SNCR

Synchronoss

$16.75

0.64 (3.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 30

    Oct

  • 19

    Sep

PG

Procter & Gamble

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Hot Stocks
Peltz says not asking for P&G CEO David Taylor to step down »

Nelson Peltz of Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOX

Amdocs

$64.13

1.64 (2.62%)

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Conference/Events
Amdocs participates in a conference call with Oppenheimer »

Conference call for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYL

Tyler Technologies

09:18
09/19/17
09/19
09:18
09/19/17
09:18
Hot Stocks
Tyler Technologies selected by Odessa, Texas for ERP solution »

Tyler Technologies signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
09/19/17
09/19
09:18
09/19/17
09:18
Options
Overnight activity included 97 trades in SPX and 67 trades in VIX »

97 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

09:16
09/19/17
09/19
09:16
09/19/17
09:16
Hot Stocks
Air Products awarded oxygen supply contract by South Korean chemical company »

Air Products has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPIC

TPI Composites

$20.98

-0.05 (-0.24%)

, XYL

Xylem

09:15
09/19/17
09/19
09:15
09/19/17
09:15
Conference/Events
Cowen to hold a summit »

Industrial Innovation…

TPIC

TPI Composites

$20.98

-0.05 (-0.24%)

XYL

Xylem

WLDN

Willdan Group

$29.79

0.71 (2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 28

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.